InflaRx N.V. (IFRX): Price and Financial Metrics

InflaRx N.V. (IFRX)

Today's Latest Price: $5.34 USD

0.42 (8.54%)

Updated Jul 16 12:54pm

Add IFRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

IFRX Daily Price Range
IFRX 52-Week Price Range

IFRX Stock Price Chart Technical Analysis Charts

IFRX Price/Volume Stats

Current price $5.34 52-week high $9.70
Prev. close $4.92 52-week low $2.17
Day low $4.92 Volume 582,623
Day high $5.47 Avg. volume 987,279
50-day MA $6.56 Dividend yield N/A
200-day MA $4.40 Market Cap 140.28M

InflaRx N.V. (IFRX) Company Bio

Fireman B.V. (InflaRx) operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. The company is based in Jena, Germany.

IFRX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

IFRX Latest Social Stream

Loading social stream, please wait...

View Full IFRX Social Stream

Latest IFRX News From Around the Web

Below are the latest news stories about InflaRx NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.

InflaRx Sees Hammer Chart Pattern: Time to Buy?

InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.

Yahoo | July 9, 2020

Hedge Funds Are Buying InflaRx N.V. (IFRX)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 25, 2020

InflaRx reports underwhelming data from study of IFX-1 in COVID-19

InflaRx (IFRX) slumps 9% premarket on average volume in reaction to preliminary data from the first 30 subjects in a Phase 2/3 clinical trial evaluating IFX-1 plus best supportive care for up to 28 days in hospitalized patients with severe COVID-19 pneumonia.There was no difference in the change from baseline to day...

Seeking Alpha | June 17, 2020

InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19

InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today interim results from the first 30 patients treated in the adaptive randomized Phase II/III trial in patients with severe COVID-19 pneumonia. The Phase II part of the study evaluated IFX-1 treatment plus best supportive care compared to best supportive care alone for up to 28 days. Relative change (%) from baseline to day 5 in oxygenation index (defined as PaO2/FiO2 ratio) was assessed as the primary endpoint along with additional clinical parameters until day 28.

Yahoo | June 17, 2020

InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions

InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | June 11, 2020

Read More 'IFRX' Stories Here

IFRX Price Returns

1-mo -25.83%
3-mo 2.69%
6-mo 46.70%
1-year 74.51%
3-year N/A
5-year N/A
YTD 34.85%
2019 -89.11%
2018 73.60%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7728 seconds.